Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 10, 2021
- Accepted in final form January 24, 2022
- First Published March 3, 2022.
Author Disclosures
- Alexandr Klistorner, PhD*,
- Samuel Klistorner, BSci* (samuel.klistorner{at}sydney.edu.au),
- Yuyi You, PhD (yuyi.you{at}gmail.com),
- Stuart L. Graham, PhD (stuart.graham{at}mq.edu.au),
- Con Yiannikas, PhD (y.con{at}bigpond.com),
- John Parratt, PhD (john.parratt{at}sydney.edu.au) and
- Michael Barnett, PhD (michael{at}snac.com.au)
- Alexandr Klistorner, PhD*,
NONE
NONE
NONE
NONE
1.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Sydney University Foundation for Medical Research 2. Sydney eye hospital foundation 3. National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Samuel Klistorner, BSci* (samuel.klistorner{at}sydney.edu.au),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yuyi You, PhD (yuyi.you{at}gmail.com),
NONE
NONE
NONE
(1) Frontiers in Neuroscience, Topic Editor, 2020-2021 (2) Annals of Eye Science, Editorial Board Member, 2020-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Health and Medical Research Council (NHMRC), #1089853, CI, 2015-2018 (2) The Ophthalmic Research Institute of Australia (ORIA), CI, 2017,2019 (3) Sydney Medical School, CI, 2016, 2019 (4) National MS Society, RG-1907-34571, PI, 2020-2024
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stuart L. Graham, PhD (stuart.graham{at}mq.edu.au),
NONE
NONE
NONE
(1)Clin Exp Ophthalmol - Glaucoma Section editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Novartis - research grant
(1)NHMRC grant CI (2)Perpetual - Hillcrest Foundation grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Con Yiannikas, PhD (y.con{at}bigpond.com),
Novartis Advisory board for Siponimod
Allergan chairman on meeting re Botox
Biogen speaker 2019 CSL speaker 2019
NONE
NONE
NONE
NONE
Consultant-Allergan,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John Parratt, PhD (john.parratt{at}sydney.edu.au) and
1. Commercial - Genzyme scientific advisory board 2. Commercial - Novartis scientific advisory board 3. Biogen advisory board 4. Sanofi advisory board 5. Roche Advisory Board
NONE
1. Commercial - Honoraria from Biogen for educational meetings 2. Commercial - Honoraria from Genzyme/Sanofi for educational meetings 3. Commercial - Honoraria from Merck Serono for 4. Commercial - Honoraria from Roche for talks educational meetings.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Multiple sclerosis research Australia Neil and Norma Hill inaugural junior practitioner fellowship
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Barnett, PhD (michael{at}snac.com.au)
Alexion: Advisory Board Novartis: Advisory Board BMS: Advisory Board
NONE
NONE
NONE
NONE
NONE
NONE
(1) RxMX: Consulting Neurologist (2) Sydney Neuroimaging Analysis Centre: Consulting Research Director
NONE
NONE
NONE
(1) Biogen: Research support to institution (2) Novartis: Research support to institution (3) BMS: Research support to institution
(1) Australian Government (MRFF and CRC grants): research support to institution Stock/Stock Options, Medical Equipment & Materials: (1) RxMx: current - spouse: minor shareholder
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Save Sight Institute (A.K., S.K., and Y.Y.), Sydney Medical School, University of Sydney, New South Wales, Australia; Faculty of Medicine and Health Sciences (A.K., Y.Y., and S.L.G.), Macquarie University, Sydney, New South Wales, Australia; Royal North Shore Hospital (S.K., C.Y., and J.P.), Sydney, New South Wales, Australia; Brain and Mind Centre (M.B.), University of Sydney, New South Wales, Australia; and Sydney Neuroimaging Analysis Centre (M.B.), Camperdown, New South Wales, Australia.
- Correspondence
Dr. Klistorner sasha{at}eye.usyd.edu.au
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
- No related articles found.